FDA clearances
This is the seventh FDA clearance for the longstanding mobile diabetes management platform.
The company has struck deals with VivaLNK and MIR, and is eying "more than 50 integrations by the end of next year."
The d-Nav Insulin Guidance Service was also the focus of a multi-center, randomized control trial published last week in the Lancet.
The new technology will be integrated into the connected MightSat Rx finger pulse oximeter.
The prescription device detects each use and records it to a paired mobile app.
The regulatory changes also come alongside Pre-Cert Program updates and roughly a dozen noteworthy digital health approvals.
The HeartGuide watch uses a flexible synthetic band to inflate and maintain its shape to comfortably take an oscillometric wrist blood pressure on the fly.